Resource for Molecular Imaging Agents in Precision Medicine

总体资源：摘要 精准医学中的分子成像试剂资源是一个跨越三个校区的项目 约翰霍普金斯大学(JHU)。在我们看来，精确医学是利用手头上关于某一特定疾病的所有数据 为病人提供尽可能好的护理。我们相信精心设计的分子成像 工程师可以对此做出贡献。我们现在准备提供一个独特的生物医学技术资源中心 (BTRC)，重点是提供化学--新试剂、方法和培训 发展和实践--用于分子成像。BTRC的生物学主题是 癌症、炎症和免疫，对其进行更深入的研究是一个尚未得到满足的需求。尽管有出色的研究 在世界范围内继续开发新的分子显像剂，几乎没有人对 解决人类的弱点和许多问题并不能证明它们的发展成本是合理的。2014年3月，NIBIB 进行了一项研究，以更好地了解为什么更多的分子显像剂和仪器 在NIH赠款支持下开发的药物既不会转化为临床，也不会随后商业化。至 解决这些缺点，JHU BTRC将通过利用翻译中心进行高度翻译 分子成像(CTMI)在约翰霍普金斯大学贝维尤医学院，F·M·柯比功能研究中心 肯尼迪·克里格研究所、癌症成像研究部和 核医学和分子成像，所有这些都高度整合到许多部门和 JHU的学校。我们已经产生了已经获得许可并正在商业化过程中的代理。 然而，到目前为止，这些活动是在临时基础上进行的，我们打算在此基础上加以扩展。 以两种新的方式：(1)提供有针对性和独特的技术研究和开发项目，这些项目将 (2)能够广泛传播和培训其使用，提高各中心和司的能力 以执行其预期的功能-发现，意图教育、促进新的协作、 跨学科研究并管理各种情况，同时解决 新兴的癌症免疫疗法。BTRC的独特之处在于它注重提供新的、精确的 材料，用于对这些材料进行临床前测试并将其用于人类，现场交付或交付给我们的合作者 以适合其实施的格式。我们将通过持续、互惠的方式确保适当的异地使用 教育和“推-拉”互动。该程序是不可知的成像方式和组成 要提供的材料，依赖于每个研发部门的具体专业知识，除了共享 利用化学进行成像，四个研发和开发将通过上述生物主题联系在一起。 它们可以简单地概括为专注于新的基因治疗(tr&d1)、分子遗传成像系统 (T&D 2)、探查免疫剂(T R&D 3)、化学交换饱和转移靶向试剂 (CEST，研发4)。在tr&ds1和d3中，也分别是临床前和临床验证核心。

OVERALL RESOURCE: Summary The Resource for Molecular Imaging Agents in Precision Medicine is a program spanning three campuses of the Johns Hopkins University (JHU). In our view precision medicine is using all data at hand regarding a particular patient to enable the best possible care for that patient. We believe that carefully designed molecular imaging agents can contribute to this. We are now poised to offer a unique Biomedical Technology Resource Center (BTRC) with a heavy emphasis on the provision of chemistry – new reagents, methods and training in their development and practice – for molecular imaging. The biological theme of the BTRC is relationships between cancer, inflammation and immunity, deeper study of which is an unmet need. Although brilliant research continues worldwide in the development of new molecular imaging agents, few have had actual impact on addressing human infirmity and many do not justify the cost of their development. In March 2014 the NIBIB conducted a study “to better understand the reasons why more molecular imaging agents and instrumentation developed with NIH grant support are not being translated to the clinic nor subsequently commercialized.” To address those shortcomings, the JHU BTRC will be highly translational by leveraging the Center for Translational Molecular Imaging (CTMI) at the Johns Hopkins Bayview medical campus, the F. M. Kirby Center for Functional Brain Imaging at the Kennedy Krieger Institute, the Division of Cancer Imaging Research, and the Division of Nuclear Medicine and Molecular Imaging, all of which are highly integrated into numerous departments and schools at JHU. We have generated agents that have been licensed and are in the process of commercialization. However to date those activities have been performed on an ad hoc basis, and we intend to expand upon them in two new ways: (1) provide targeted and unique technical research and development (TR&D) projects that will (2) enable widespread dissemination and training in their use, enhancing the capacity of the centers and divisions noted above to perform their intended functions – discovery with intent to educate, promote new collaborative, transdisciplinary research and to manage a variety of conditions, while addressing unanticipated effects of emerging cancer immunotherapies. The unique aspect of the BTRC is its focus on provision of new, precision materials, to test these pre-clinically and progress them to human use, delivered on-site or to our collaborators in a format suitable for their implementation. We will assure proper off-site utilization through continual, reciprocal education and “push-pull” interactions. The program is agnostic to imaging modality and composition of the materials to provide, relying upon the specific expertise within each TR&D. In addition to sharing the goal of leveraging chemistry for imaging, the four TR&Ds will be linked through the aforementioned biological theme. They can briefly be summarized as focusing on new theranostics (TR&D 1), molecular-genetic imaging systems (TR&D 2), agents for probing immunity (TR&D 3), and targeted agents for chemical exchange saturation transfer (CEST, TR&D 4). Within TR&Ds 1 and 3 are also the Pre-clinical and Clinical Validation cores, respectively.